Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVBOcugen Inc. (
NASDAQOCGN) emerges as a noteworthy biotech stock for investors to monitor in upcoming trading sessions. On February 22, 2024, Ocugen Inc. reported the successful completion of the initial cohort in the Phase 1/2 GARDian clinical trial for its OCU410ST product. This product, a modifier gene therapy candidate, aims to address Stargardt disease, an orphan blindness condition affecting approximately 35,000 individuals solely in the United States. Dr. Arun Upadhyay, Ocugen’s Head of Research and Development and Chief Scientific Officer highlighted this achievement as a significant clinical milestone for the company. OCU410ST represents a pioneering, potentially one-time therapy for Stargardt disease sufferers. With a surge in after-hours trading on February 26, 2024, keeping a close watch on Ocugen's stock performance could prove prudent.
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDSLately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments.
Sidoti Microcap Virtual ConferencePresentation Times Released for 50 Presenting Companies Wednesday and Thursday, August 18-19, 2021 NEW YORK, NY / ACCESSWIRE / August 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day summer Microcap Virtual Conference taking place Wednesday and Thursday, August 18 - 19, 2021. The links can also be found at www.sidoticonference.com/events. Group Presentation Schedule Click Here to Login /
